Fresh raspberry phytochemical extract inhibits hepatic lesion in a Wistar rat model.
BACKGROUND
Red raspberry possesses potent antioxidant capacity and antiproliferative activity against cancer in vitro.


METHODS
The objective of this study was to determine the protective effects of raspberry 80% acetone extract in a rat hepatic lesions model induced by diethylnitrosamine (DEN). Rats were treated with the red raspberry extract (0.75, 1.5 or 3.0 g/kg of body weight) by gavage starting 2 h after DEN administration and continuing for 20 weeks.


RESULTS
A dose-dependent inhibition by red raspberry extract of DEN-induced hepatic nodule formation which stands for hepatic lesions was observed. Corresponding hepatic nodule incidence rates were 45.0, 40.0, 25.0 and 5.0% in positive control, low, middle and high groups, respectively (P < 0.01 or 0.05). Gross findings, histopathological and ultrastructural evaluations of hepatic lesion were performed on 9, 8, 5 and 1 hepatic nodule in positive control, low, middle and high doses of groups, respectively, identified in rats from the respective groups of 20. A decreasing trend of proportions of hepatocellular carcinoma masses accompanied the increasing doses of red raspberry extract.


CONCLUSIONS
These findings demonstrate that the potent capacity of red raspberry diet could not only suppress DEN-induced hepatic lesions in rats, but also reduce the definite diagnostic features of neoplasm.
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, 37 YiYuan Street, NanGang District, Harbin, 150001, The People's Republic of China.
Yan
Y
Liu
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, 37 YiYuan Street, NanGang District, Harbin, 150001, The People's Republic of China.
Ming
M
Liu
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, 37 YiYuan Street, NanGang District, Harbin, 150001, The People's Republic of China.
Bin
B
Li
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, 37 YiYuan Street, NanGang District, Harbin, 150001, The People's Republic of China.
Jin-Lu
JL
Zhao
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, 37 YiYuan Street, NanGang District, Harbin, 150001, The People's Republic of China.
Chun-Peng
CP
Zhang
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, 37 YiYuan Street, NanGang District, Harbin, 150001, The People's Republic of China.
Luo-Qiang
LQ
Lin
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, 37 YiYuan Street, NanGang District, Harbin, 150001, The People's Republic of China.
Hong-Sheng
HS
Chen
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, 37 YiYuan Street, NanGang District, Harbin, 150001, The People's Republic of China.
Shu-Jun
SJ
Zhang
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, 37 YiYuan Street, NanGang District, Harbin, 150001, The People's Republic of China.
Jun-Chao
JC
Jin
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, 37 YiYuan Street, NanGang District, Harbin, 150001, The People's Republic of China.
Lei
L
Wang
The Affiliated Tumor Hospital of Harbin Medical University, 6 BaoJian Road, NanGang District, Harbin, 150086, The People's Republic of China.
Le-Jing
LJ
Li
Public Health College, Harbin Medical University, 157 BaoJian Road, NanGang District, Harbin, 150081, The People's Republic of China.|Jia-Ren Liu at Harvard Medical School, 300 Longwood Ave, Boston, MA, USA.
Jia-Ren
JR
Liu